A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in
12-week cycles to patients with unresectable or borderline resectable locally advanced
pancreatic cancer combined with chemotherapy treatment.
Primary Outcome:
- ORR at 6 months.